Hologic, Inc. (HOLX) Stock

HOLX logo

Hologic, Inc.

HOLX
Healthcare

Company profile

Hologic reported revenue of $4.10 billion for fiscal year 2025, up 1.7% from fiscal year 2024, and net income of $565.70 million. That is a net profit margin of 13.8% for fiscal year 2025. In Q1 2026 (the quarter ended December 31, 2025) revenue was $1.05 billion, up 2.5% from a year before. Its largest business segment, Diagnostics, brought in 45% of segment revenue in fiscal year 2025; United States was the largest region with 74%. In Q1 2026 it reported net income of $179.10 million, against net income of $201.00 million a year earlier. Our analysis of its filings shows revenue growing from $4.03 billion in fiscal year 2023 to $4.10 billion in fiscal year 2025, 0.9% a year on average.

Figures from company filings; latest fiscal year ended September 30, 2025.

Largest shareholders

  • Vanguard Fiduciary Trust Co.11.22%
  • T. Rowe Price Investment Management, Inc.10.73%
  • BlackRock Advisors LLC6.64%
  • Manulife Financial Corporation4.91%
  • State Street Corporation4.50%

Share of the company, as of November 8, 2025

How much revenue does Hologic make?

Hologic reported $4.10 billion in revenue for fiscal year 2025, up 1.7% from $4.03 billion in fiscal year 2024. In Q1 2026 revenue was $1.05 billion.

What is Hologic's largest business segment?

Diagnostics, with $1.83 billion or 45% of segment revenue in fiscal year 2025. Next: Breast Health (36%) and GYN Surgical (17%).

Where does Hologic make most of its revenue?

United States: 74% of revenue by region in fiscal year 2025, followed by Europe (14%).

What companies are similar to Hologic?

Listed companies of a similar size in the same industry (various healthcare equipment manufacturing) include Terumo Corporation (4543.T), PharmaResearch Co., Ltd. (214450.KQ), Olympus Corporation (7733.T), Fukuda Denshi Co., Ltd. (6960.T).

Company Information

SectorHealthcare
IndustryVarious Healthcare Equipment Manufacturing
Founded1985
IPO DateMar 9, 1990
IPO StatusPublic
FoundersJay Stein
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Hologic, Inc. (HOLX)”, data as of Dec 31, 2025, https://dataporium.tech/stocks/HOLX

LinkedInLinkedInXXYouTubeYouTube